PartnershipMay 27, 2026, 04:12 PM
Aptevo, Niowave Form 50/50 Radiopharmaceutical Collaboration; Niowave Invests $500K
AI Summary
Aptevo Therapeutics Inc. and Niowave, Inc. announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, combining Aptevo's proprietary molecules and multispecific antibody platforms with Niowave's radioisotopes and supply capabilities. Concurrently, Niowave made an initial equity investment of approximately $500,000 in Aptevo, acquiring 98,522 common shares and warrants for 53,201 shares, representing an initial 7.9% ownership. Niowave has the potential to increase its stake to up to 19.99% through additional purchases and warrant exercises. This partnership marks Aptevo's expansion into the radiopharmaceutical therapeutic development space.
Key Highlights
- Aptevo and Niowave formed a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs.
- Niowave made an initial equity investment of approximately $500,000 in Aptevo.
- Niowave acquired 98,522 common shares and warrants for 53,201 shares in the initial private placement.
- The initial investment gives Niowave an ownership position of 7.9% in Aptevo.
- Warrants are exercisable at $8.00 per share and expire on May 25, 2031.
- Niowave has the potential to increase its equity stake to up to 19.99% through future purchases and warrant exercises.
- Aptevo contributes multispecific antibody platforms; Niowave provides radioisotopes like Actinium-225.
Price Impact
More from APVO